Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Endocrine
Published in: Endocrine 3/2016

01-12-2016 | New horizons in

Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines

Authors: Gherardo Mazziotti, Anna Maria Formenti, Robert A. Adler, John P. Bilezikian, Ashley Grossman, Emilia Sbardella, Salvatore Minisola, Andrea Giustina

Published in: Endocrine | Issue 3/2016

Login to get access

Abstract

Glucocorticoid-induced osteoporosis is the most frequent form of secondary osteoporosis caused by chronic exposure to glucocorticoid excess. Pathogenesis of glucocorticoid-induced osteoporosis is multifactorial including direct effects of glucocorticoids on bone cells and indirect effects of glucocorticoids on several neuroendocrine and metabolic pathways. Fragility fractures occur early in glucocorticoid-induced osteoporosis and anti-osteoporotic drugs along with calcium and vitamin D should be started soon after exposure to glucocorticoid excess. This paper summarizes some of the main topics discussed during the 9th Glucocorticoid-Induced Osteoporosis Meeting (Rome, April 2016) with a specific focus on the role of growth hormone/insulin-like growth factor-1 and parathyroid hormone/vitamin D axes in the pathogenesis of glucocorticoid-induced osteoporosis and the controversial aspects concerning therapeutic approach to skeletal fragility in this clinical setting.
Literature
1.
E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328 (2007)CrossRefPubMed
2.
A. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: summary of a workshop. J. Clin. Endocrinol. Metab. 86, 5681–5685 (2001)CrossRefPubMed
3.
T. Mancini, M. Doga, G. Mazziotti, A. Giustina, Cushing’s syndrome and bone. Pituitary 7, 1–4 (2005)CrossRef
4.
G. Mazziotti G, A. Delgado, F. Maffezzoni, A. Formenti, A. Giustina, Skeletal fragility in endogenous hypercortisolism. Front. Horm. Res. 46, 66–73 (2016)CrossRefPubMed
5.
P. Vestergaard, J. Lindholm, J.O. Jørgensen, C. Hagen, H.C. Hoeck, P. Laurberg, L. Rejnmark, K. Brixen, L.O. Kristensen, U. Feldt-Rasmussen, L. Mosekilde, Increased risk of osteoporotic fractures in patients with Cushing’s syndrome. Eur. J. Endocrinol. 146, 51–56 (2002)CrossRefPubMed
6.
A. Scillitani, G. Mazziotti, C. Di Somma, S. Moretti, A. Stigliano, R. Pivonello, A. Giustina, A. Colao; ABC group, treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos. Int. 25, 441–446 (2015)CrossRef
7.
G. Mazziotti, A. Angeli, J.P. Bilezikian, E. Canalis, A. Giustina, Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol. Metab. 17, 144–149 (2006)CrossRefPubMed
8.
N.E. Lane, W. Yao, M. Balooch, R.K. Nalla, G. Balooch, S. Habelitz, J.H. Kinney, L.F. Bonewald, Glucocorticoid treated mice have localized changes in trabecular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21, 466–476 (2006)CrossRefPubMed
9.
T.P. Van Staa, R.F. Laan, I.P. Barton, S. Cohen, D.M. Reid DM, C. Cooper, Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224–3229 (2003)CrossRefPubMed
10.
G. Mazziotti, A. Giustina, Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol 9, 265–276 (2013)CrossRefPubMed
11.
C.E. Dean, B. Morpurgo, T.E. Porter, Induction of somatotroph differentiation in vivo by corticosterone administration during chicken embryonic development. Endocrine 11, 151–156 (1999)CrossRefPubMed
12.
A. Giustina, J.D. Veldhuis, Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev. 19, 717–797 (1998)PubMed
13.
A. Tamaki, M. Sato, S. Matsubara, Y. Wada, J. Takahara, Dexamethasone increases growth hormone (GH)-releasing hormone (GHR) receptor mRNA levels in culture rat anterior pituitary cells. Neuroendocrinology 8, 475–480 (1996)CrossRef
14.
A. Giustina, G. Romanelli, R. Candrina, G. Giustina, Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. J. Clin. Endocrinol. Metab. 68, 120–124 (1989)CrossRefPubMed
15.
Y. Hattori, T. Takeda, M. Fujii, J. Taura, Y. Ishii, H. Yamada, Dioxin-induced fetal growth retardation: the role of a preceding attenuation in the circulating level of glucocorticoid. Endocrine 47, 572–580 (2014)CrossRefPubMed
16.
A. Giustina, G. Mazziotti, Impaired growth hormone secretion associated with low glucocorticoid levels: an experimental model for the Giustina effect. Endocrine 47, 354–356 (2014)CrossRefPubMed
17.
W.B. Wehrenberg, P.J. Bergman, L. Stagg, J. Ndon, A. Giustina, Glucocorticoid inhibition of growth in rats: partial reversal with somatostatin antibodies. Endocrinology 127, 2705–2708 (1990)CrossRefPubMed
18.
G. Tulipano, D. Soldi, M. Bagnasco, M.D. Culler, J.E. Taylor, D. Cocchi, A. Giustina, Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. Endocrinology 143, 1218–1224 (2002)CrossRefPubMed
19.
A. Giustina, S. Bossoni, C. Bodini, A. Girelli, G.P. Balestrieri, G. Pizzocolo, W.B. Wehrenberg, Arginine normalizes the growth hormone (GH) response to GH-releasing hormone in adult patients receiving chronic daily immunosuppressive glucocorticoid therapy. J. Clin. Endocrinol. Metab. 74, 1301–1305 (1992)PubMed
20.
A. Giustina, M. Doga, C. Bodini, A. Girelli, F. Legati, S. Bossoni, G. Romanelli, Acute effects of cortisone acetate on growth hormone response to growth hormone-releasing hormone in normal adult subjects. Acta Endocrinol. 122, 206–210 (1990)PubMed
21.
M. Malerba, S. Bossoni, A. Radaeli, E. Mori, S. Bonadonna, A. Giustina, C. Tantucci, Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment. Chest 127, 515–521 (2005)CrossRefPubMed
22.
M. Terzolo, S. Bossoni, A. Alı, M. Doga, G. Reimondo, G. Milani, P. Peretti, F. Manelli, A. Angeli, A. Giustina, Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone. J. Clin. Endocrinol. Metab. 85, 1310–1315 (2000)CrossRefPubMed
23.
Z. Hochberg, Mechanisms of steroid impairment of growth. Horm. Res. 58, S33–S38 (2002)
24.
H. Filipsson, G. Johannsson, GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. Eur. J. Endocrinol. 161, S85–S95 (2009)CrossRefPubMed
25.
26.
A. Angeli, G. Guglielmi, A. Dovio, G. Capelli, D. de Feo, S. Giannini, R. Giorgino, L. Moro, A. Giustina, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39, 253–259 (2006)CrossRefPubMed
27.
G. Mazziotti, M. Doga, S. Frara, F. Maffezzoni, T. Porcelli, L. Cerri, R. Maroldi, A. Giustina, Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency. Endocrine 52, 103–110 (2016)CrossRefPubMed
28.
A. Giustina, A.R. Bussi, C. Jacobello, W.B. Wehrenberg, Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J. Clin. Endocrinol. Metab. 80, 122–129 (1995)PubMed
29.
F.F. Horber, M.W. Haymond, Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J. Clin. Invest. 86, 265–272 (1990)CrossRefPubMedPubMedCentral
30.
M.A. Magiakou, G.P. Chrousos GP, Cushing’s syndrome in children and adolescents: current diagnostic and therapeutic strategies. J. Endocrinol. Invest. 25, 181–194 (2002)CrossRefPubMed
31.
R.G. McArthur, M.D. Cloutier, A.B. Hayles, R.G. Sprague, Cushing’s disease in children. Findings in 13 cases. Mayo. Clin. Proc. 47, 318–326 (1972)PubMed
32.
D.H. Streeten, F.H. Faas, M.J. Elders, T.G. Dalakos, M. Voorhess, Hypercortisolism in childhood: shortcomings of conventional diagnostic criteria. Pediatrics 56, 797–803 (1975)PubMed
33.
34.
M.A. Magiakou, G. Mastorakos, G.P. Chrousos, Final stature in patients with endogenous Cushing’s syndrome. J. Clin. Endocrinol. Metab. 79, 1082–1085 (1994)PubMed
35.
N.R. Hughes, C.A. Lissett, S.M. Shalet, Growth hormone status following treatment for Cushing’s syndrome. Clin. Endocrinol. (Oxf). 51, 61–66 (1999)CrossRefPubMed
36.
M.A. Magiakou, G. Mastorakos, M.T. Gomez, S.R. Rose, G.P. Chrousos, Suppressed spontaneous and stimulated growth hormone secretion in patients with Cushing’s disease before and after surgical cure. J. Clin. Endocrinol. Metab. 78, 131–137 (1994)PubMed
37.
M.O. Savage, A. Lienhardt, M.C. Lebrethon, L.B. Johnston, A. Huebner, A.B. Grossman, F. Afshar, P.N. Plowman, G.M. Besser, Cushing’s disease in childhood: presentation, investigation, treatment and long-term outcome. Horm. Res. 55(Suppl 1), 24–30 (2001)PubMed
38.
M.C. Lebrethon, A.B. Grossman, F. Afshar, P.N. Plowman, G.M. Besser, M.O. Savage, Linear growth and final height after treatment for Cushing’s disease in childhood. J. Clin. Endocrinol. Metab. 85, 3262–3265 (2000)PubMed
39.
L.F. Chan, H.L. Storr, P.N. Plowman, L.A. Perry, G.M. Besser, A.B. Grossman, M.O. Savage, Long-term anterior pituitary function in patients with paediatric Cushing’s disease treated with pituitary radiotherapy. Eur. J. Endocrinol. 156, 477–482 (2007)CrossRefPubMed
40.
V. Khanine, J.J. Fournier, E. Requeda, J.P. Luton, F. Simon, J. Crouzet, Osteoporotic fractures at presentation of Cushing’s disease: two case reports and a literature review. Joint Bone Spine 67, 341–345 (2000)PubMed
41.
L. Futo, J. Toke, A. Patocs, A. Szappanos, I. Varga, E. Glaz, Z. Tulassay, K. Racz, M. Toth, Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing’s syndrome. Osteoporos. Int. 19, 941–949 (2008)CrossRefPubMed
42.
K. Godang, T. Ueland, J. Bollerslev, Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing’s syndrome. Eur. J. Endocrinol. 141, 126–131 (1999)CrossRefPubMed
43.
A.R. Hermus, A.G. Smals, L.M. Swinkels, D.A. Huysmans, G.F. Pieters, C.F. Sweep, F.H. Corstens, P.W. Kloppenborg PW, Bone mineral density and bone turnover before and after surgical cure of Cushing’s syndrome. J. Clin. Endocrinol. Metab. 80, 2859–2865 (1995)PubMed
44.
A. Kawamata, M. Iihara, T. Okamoto, T. Obara, Bone mineral density before and after surgical cure of Cushing’s syndrome due to adrenocortical adenoma: prospective study. World J. Surg. 32, 890–896 (2008)CrossRefPubMed
45.
A.W. van der Eerden, M. den Heijer, W.J. Oyen, A.R. Hermus, Cushing’s syndrome and bone mineral density: lowest Z scores in young patients. Neth. J. Med. 65, 137–141 (2007)PubMed
46.
C. Di Somma, R. Pivonello, S. Loche, A. Faggiano, P. Marzullo, A. Di Sarno, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Severe impairment of bone mass and turnover in Cushing’s disease: comparison between childhood-onset and adulthood-onset disease. Clin. Endocrinol. 56, 153–158 (2002)CrossRef
47.
D.J. Devoe, W.L. Miller, F.A. Conte, S.L. Kaplan, M.M. Grumbach, S.M. Rosenthal, C.B. Wilson, S.E. Gitelman, Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing’s disease. J. Clin. Endocrinol. Metab. 82, 3196–3202 (1997)PubMed
48.
C. Di Somma, R. Pivonello, S. Loche, A. Faggiano, M. Klain, M. Salvatore, G. Lombardi, A. Colao, Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing’s disease: a prospective study. Clin. Endocrinol. 58, 302–308 (2003)CrossRef
49.
I. Jeong, M. Oh, J.H. Kim, J.H. Cho, J.H. Choi, H.W. Yoo, Long-term follow-up on Cushing disease patient after transsphenoidal surgery. Ann. Pediatr. Endocrinol. Metab. 19, 164–168 (2014)CrossRefPubMedPubMedCentral
50.
S. Scommegna, J.P. Greening, H.L. Storr, K.M. Davies, N.J. Shaw, J.P. Monson, A.B. Grossman, M.O. Savage, Bone mineral density at diagnosis and following successful treatment of pediatric Cushing’s disease. J. Endocrinol. Invest. 28, 231–235 (2005)CrossRefPubMed
51.
G.M. Leong, L.B. Mercado-Asis, J.C. Reynolds, S.C. Hill, E.H. Oldfield, G.P. Chrousos, : The effect of Cushing’s disease on bone mineral density, body composition, growth, and puberty: a report of an identical adolescent twin pair. J. Clin. Endocrinol. Metab. 81, 1905–1911 (1996)PubMed
52.
G.M. Leong, V. Abad, E. Charmandari, J.C. Reynolds, S. Hill, G.P. Chrousos, L.K. Nieman, Effects of child- and adolescent-onset endogenous cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. J. Bone Miner. Res. 22, 110–118 (2007)CrossRefPubMed
53.
M.B. Lodish, H.P. Hsiao, A. Serbis, N. Sinaii, A. Rothenbuhler, M.F. Keil, S.A. Boikos, J.C. Reynolds, C.A. Stratakis, Effects of Cushing disease on bone mineral density in a pediatric population. J. Pediatr. 156, 1001–1005 (2010)CrossRefPubMedPubMedCentral
54.
55.
S.M. Tse, H.W. Kelly, A.A. Litonjua, M.L. Van Natta, S.T. Weiss, K.G. Tantisira; Childhood Asthma Management Program Research Group, Corticosteroid use and bone mineral accretion in children with asthma: effect modification by vitamin D. J. Allergy Clin. Immunol. 130, 53–60 (2012)CrossRefPubMedPubMedCentral
56.
Z.E. Davidson, K.Z. Walker, H. Truby, Do glucocorticoids alter vitamin D status? A systematic review with meta-analyses of observational studies. J. Clin. Endocrinol. Metab. 97, 738–744 (2012)CrossRefPubMed
57.
E. Romagnoli, J. Pepe, S. Piemonte, C. Cipriani, S. Minisola, Management of endocrine disease: value and limitations of assessing vitamin D nutritional status and advised levels of vitamin D supplementation. Eur. J. Endocrinol. 169, R59–R69 (2013)CrossRefPubMed
58.
C. Cipriani, J. Pepe, S. Piemonte, L. Colangelo, M. Cilli, S. Minisola, Vitamin d and its relationship with obesity and muscle. Int. J. Endocrinol. 2014, 841248 (2014)CrossRefPubMedPubMedCentral
59.
S. Huybers, T.H. Naber, R.J. Bindels, J.G. Hoenderop, Prednisolone-induced Ca2+ malabsorption is caused by diminished expression of the epithelial Ca2+ channel TRPV6. Am. J. Physiol. Gastrointest. Liver Physiol. 292, G92–G97 (2007)CrossRefPubMed
60.
J. Pepe, E. Romagnoli, I. Nofroni, M.T. Pacitti, S. De Geronimo, C. Letizia, G.,G. Tonnarini, A. Scarpiello, E. D’Erasmo, S. Minisola, Vitamin D status as the major factor determining the circulating levels of parathyroid hormone: a study in normal subjects. Osteoporos. Int. 16, 805–812 (2005)CrossRefPubMed
61.
E. Paz-Pacheco, G. El-Hajj Fuleihan, M. Leboff, Intact parathyroid hormone levels are not elevated in glucocorticoid-treated subjects. J. Bone Miner. Res. 10, 1713–1718 (1995)CrossRefPubMed
62.
S. Bonadonna, A. Burattin, M. Nuzzo, G. Bugari, E. Agabiti-Rosei, D. Valle, N. Iori, J.P. Bilezikian, J.D. Veldhuis, A. Giustina, Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur. J. Endocrinol. 152, 199–205 (2005)CrossRefPubMed
63.
K.E. Hansen, H.A. Wilson, C. Zapalowski, H.A. Fink, S. Minisola, R.A. Adler, Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J. Bone Miner. Res. 26, 1989–96 (2011)CrossRefPubMed
64.
J.M. Grossman, R. Gordon, V.K. Ranganath, C. Deal, L. Caplan, W. Chen, J.R. Curtis, D.E. Furst, M. McMahon, N.M. Patkar, E. Volkmann, K.G. Saag, American college of rheumatology recommendations for the prevention and treatment of glucocorticoid induced osteoporosis. Arthritis Care Res. 62, 1515–1526 (2010)CrossRef
65.
S. Lekamwasam, J.D. Adachi, D. Agnusdei, J.P. Bilezikian, S. Boonen, F. Borgström, C. Cooper, A. Diez Perez, R. Eastell, L.C. Hofbauer, J.A. Kanis, B.L. Langdahl, O. Lesnyak, R. Lorenc, E. McCloskey, O.D. Messina, N. Napoli, B. Obermayer-Pietsch, S.H. Ralston, P.N. Sambrook, S. Silverman, M. Sosa, J. Stepan, G. Suppan, D.A. Wahl, J.E. Compston; Joint IOF-ECTS GIO Guidelines Working Group, A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis Int. 23, 2257–2276 (2012)CrossRef
66.
A.C. Ross, J.E. Manson, S.A. Abrams, J.F. Aloia, P.M. Brannon, S.K. Clinton, R.A. Durazo-Arvizu, J.C. Gallagher, R.L. Gallo, G. Jones, C.S. Kovacs, S.T. Mayne, C.J. Rosen, S.A. Shapses, The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96, 53–58 (2011)CrossRefPubMed
67.
R.P. Heaney, M.F. Holick, Why the IOM recommendations for vitamin D are deficient. J. Bone Miner. Res. 26, 455–457 (2011)CrossRefPubMed
68.
K.G. Saag, R. Emkey, T.J. Schnitzer, J.P. Brown, F. Hawkins, S. Goemaere, G. Thamsborg, U.A. Liberman, P.D. Delmas, M.P. Malice, M. Czachur, A.G. Daifotis, Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced osteoporosis intervention study group. N. Engl. J. Med. 339, 292–299 (1998)CrossRefPubMed
69.
J.D. Adachi, K.G. Saag, P.D. Delmas, U.A. Liberman, R.D. Emkey, E. Seeman, N.E. Lane, J.M. Kaufman, P.E. Poubelle, F. Hawkins, R. Correa-Rotter, C.J. Menkes, J.A. Rodriguez-Portales, T.J. Schnitzer, J.A. Block, J. Wing, H.H. McIlwain, R. Westhovens, J. Brown, J.A. Melo-Gomes, B.L. Gruber, M.J. Yanover, M.O. Leite, K.G. Siminoski, M.C. Nevitt, J.T. Sharp, M.P. Malice, T. Dumortier, M. Czachur, W. Carofano, A. Daifotis, Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202–211 (2001)CrossRefPubMed
70.
S. Wallach, S. Cohen, D.M. Reid, R.A. Hughes, D.J. Hosking, R.F. Laan, S.M. Doherty, M. Maricic, C. Rosen, J. Brown, I. Barton, A.A. Chines, Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277–285 (2000)CrossRefPubMed
71.
D.M. Reid, J.P. Devogelaer, K.G. Saag, C. Roux, C.S. Lau, J.Y. Reginster, P. Papanastasiou, A. Ferreira, F. Hartl, T. Fashola, P. Mesenbrink, P.N. Sambrook; HORIZON investigators, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253–1263 (2009)CrossRefPubMed
72.
T. Petranova, I. Sheytanov, S. Monov, R. Nestorova, R. Rashkov, Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment. Biotechnol. Biotechnol. Equip. 28, 1127–1137 (2014)CrossRefPubMedPubMedCentral
73.
C.C. Mok, L.Y. Ho, K.M. Ma, Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone 75, 222–228 (2015)CrossRefPubMed
74.
T. Takeuchi, Y. Tanaka, N. Ishiguro, H. Yamanaka, T. Yoneda, T. Ohira, N. Okubo, H.K. Genant, D. van der Heijde, Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with rheumatoId arthritis on methotrexate to validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial. Ann. Rheum. Dis. 75, 983–990 (2016)CrossRefPubMed
75.
L. Gennari, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: hope on the HORIZON. Lancet 373, 1225–1226 (2009)CrossRefPubMed
76.
K.G. Saag, E. Shane, S. Boonen, F. Marín, D.W. Donley, K.A. Taylor, G.P. Dalsky, R. Marcus, Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Eng. J. Med. 357, 2028–2039 (2007)CrossRef
77.
K.G. Saag, J.R. Zanchetta, J.P. Devogelaer, R.A. Adler, R. Eastell, K. See, J.H. Krege, K. Krohn, M.R. Warner, Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346–3355 (2009)CrossRefPubMed
78.
J.P. Devogelaer, R.A. Adler, C. Recknor, K. See, M.R. Warner, M. Wong, K. Krohn, Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J. Rheumatol. 37, 141–148 (2010)CrossRefPubMed
79.
B.L. Langdahl, F. Marin, E. Shane, H. Dobnig, J.R. Zanchetta, M. Maricic, K. Krohn, K. See, M.R. Warner, Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporosis Int. 12, 2095–2104 (2009)CrossRef
80.
C.C. Glüer, F. Marin, J.D. Ringe, F. Hawkins, R. Möricke, N. Papaioannu, P. Farahmand, S. Minisola, G. Martínez, J.M. Nolla, C. Niedhart, N. Guañabens, R. Nuti, E. Martín-Mola, F. Thomasius, G. Kapetanos, J. Peña, C. Graeff, H. Petto, B. Sanz, A. Reisinger, P.K. Zysset, Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J. Bone Miner. Res. 28, 1355–1368 (2013)CrossRefPubMedPubMedCentral
81.
G. Mazziotti, F. Maffezzoni, M. Doga, L.C. Hofbauer, R.A. Adler, A. Giustina, Outcome of glucose homeostasis in patients with glucocorticoid-induced osteoporosis undergoing treatment with bone active-drugs. Bone 67, 175–180 (2014)CrossRefPubMed
82.
K. Briot, B. Cortet, C. Roux, L. Fardet, V. Abitbol, J. Bacchetta, D. Buchon, F. Debiais, P. Guggenbuhl, M. Laroche, E. Legrand, E. Lespessalilles, C. Marcelli, G. Weryha, T. Thomas, Bone section of the french society for rheumatology (SFR) and osteoporosis research and information group (GRIO). Joint Bone Spine 81, 493–501 (2014)CrossRefPubMed
83.
H.O. Tory, D.H. Solomon, S.P. Desai, Analysis of quality improvement efforts in preventing glucocorticoid-induced osteoporosis. Sem. Arthritis Rheum. 44, 483–488 (2015)CrossRef
84.
A.H. Warriner, R.C. Outman, J.J. Allison, J.R. Curtis, N.J. Markward, D.T. Redden, M.M. Safford, E.J. Stanek, A.R. Steinkellner, K.G. Saag, An internet-based controlled trial aimed to improve osteoporosis prevention among chronic glucocorticoid users. J. Rheumatol. 42, 1478–1483 (2015)CrossRefPubMed
85.
J.R. Curtis, A.O. Westfall, J. Allison, Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial. Arch. Intern. Med. 167, 591–596 (2007)CrossRefPubMed
86.
D.H. Solomon, J.N. Katz, J.P. Jacobs, A.M. La Tourette, J. Coblyn, Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial. Arthritis Rheum. 51, 383–387 (2004)CrossRefPubMed
87.
M.J. Kohler, M. Amezaga, J. Drozd, S.T. Crowley, B. Gulanski, D.R. Anderson, L. Fraenkel, Use of a computerized order set to increase prescription of calcium and vitamin D supplementation in patients receiving glucocorticoids. J. Gen. Intern. Med. 28, 825–829 (2013)CrossRefPubMedPubMedCentral
88.
E.D. Newman, C.K. Matzko, T.P. Olenginski, J.L. Perruquet, T.M. Harrington, G. Maloney-Saxon, T. Culp, G.C. Wood, Glucocorticoid-induced osteoporosis program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at1 year. Osteoporos. Int. 17, 1428–1434 (2006)CrossRefPubMed
Metadata
Title
Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/VITAMIN D axes, treatment options and guidelines
Authors
Gherardo Mazziotti
Anna Maria Formenti
Robert A. Adler
John P. Bilezikian
Ashley Grossman
Emilia Sbardella
Salvatore Minisola
Andrea Giustina
Publication date
01-12-2016
Publisher
Springer US
Published in
Endocrine / Issue 3/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-016-1146-8

Other articles of this Issue 3/2016

Endocrine 3/2016 Go to the issue

Original Article

Searching for the most effective thyrotropin (TSH) threshold to rule-out autonomously functioning thyroid nodules in iodine deficient regions

Original Article

TGR5 suppresses high glucose-induced upregulation of fibronectin and transforming growth factor-β1 in rat glomerular mesangial cells by inhibiting RhoA/ROCK signaling

Letter to the Editor

Physical exercise and dementia in patients with type 2 diabetes mellitus

Editorial

Fish scale is a suitable model for analyzing determinants of skeletal fragility in type 2 diabetes

Original Article

Modifiable risk factors for gestational diabetes recurrence

Original Article

Interleukins 6 and 8 and abdominal fat depots are distinct correlates of lipid moieties in healthy pre- and postmenopausal women
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits